Brege Laura 4

What Happened
Laura Brege, a director of Pacira BioSciences (PCRX), was granted equity awards on 2026-06-10: 6,405 restricted stock units (RSUs) and a separate derivative award of 10,891 units. Both awards are reported at $0.00 (grant), so no cash was exchanged. The RSUs represent the contingent right to one share each; the derivative award is an option-like award that becomes exercisable subject to vesting conditions.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Grants: 6,405 RSUs @ $0.00; 10,891 derivative award units @ $0.00.
• Vesting: Both awards vest (or become exercisable) on June 10, 2027, contingent on continuous service (see footnotes).
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 — each RSU converts to one share if Brege remains in service through 6/10/2027. F2 — the derivative/option vests and becomes exercisable on 6/10/2027, contingent on continued service.
• No sale or exercise occurred — these are grants/compensation awards, not open-market purchases or sales.

Context
These awards are typical director compensation and do not reflect an immediate purchase or sale of stock. RSUs convert to shares only if vesting conditions are met; the derivative award similarly must vest before exercise is possible. Such grants disclose potential future dilution but are not direct indicators of near-term insider buying or selling.